More all-time highs are in the books for the major averages as a temporary fix to the government shutdown come through and earnings season starts off hot
But the real action is in happening in biotech stocks. A couple of big buyouts paved the way for some impressive biotech gains to kick off the new trading week.
First up, Celgene Corp. (NADSAQ:CELG) plunked down $9 billion to acquire Juno Therapeutics (NASDAQ:JUNO) and get ahold of its promising line of CAR-T cancer treatments. The announcement juiced JUNO shares by more than 25% on the day, bringing its five day gains to an eye-popping....More>>>
Investing in biotechs can be an exercise in frustration, as Lexicon Pharmaceuticals (NASDAQ:LXRX) so amply demonstrates. While I believe the company has continued to build a solid case that its dual SGLT-1/2 inhibitor sotagliflozin can and should be approved for use in Type 1 diabetes, the shares are down about 20% from the time of my last update. Although the data package on sotagliflozin is not perfect, I believe it shows acceptable safety and worthwhile efficacy for a patient group with virtually no medical treatment options beyond insulin.
InTandem2 Comes In Pretty Much As Expected
As biotech stocks like Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) get ready to report earnings, Piper Jaffray’s Joshua Schimmer and team write that they “would not be surprised to see the volatility continue.” They explain why:
Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance,....More>>>
Boring industries and small-capitalization stocks are two things that are very rarely found together. If you search the ranks of the hottest or most promising small-cap stocks, you will find mostly technology and biotech.
So, when I stumbled upon Fuling Global (NASDAQ:FORK), a Chinese manufacturer of plastic cutlery, plates, cups, straws, and similar products, the valuation and growth rate made me both suspicious and excited at first glance.
Upon more investigation, I really liked the company and felt the market was underpricing the risks inherent in the company.....More>>>
ImmunoGen (NASDAQ:IMGN) is a clinical stage biotech company that is focused on cancer therapeutics. It has developed an antibody-drug conjugate or “ADC” technology which is already being used in an approved and marketed product and is also being developed for use in a few other clinical stage candidates that are part of ImmunoGen’s current pipeline. The lead pipeline candidate for this company is called “Mirvetuximab Soravtansine”. This will be tested as an ovarian cancer treatment in Phase 3 trials which are expected to commence very soon. Obviously, this company....More>>>